Composition for prostaglandin transporter inhibition and related therapeutic applications

Abstract

The present invention discloses a composition comprising Allium sativum extract standardized to contain not less that 0.3% w/w S-allylcysteine, Beta vulgaris extract standardized to contain not less than 2% w/w nitrates, Nigella sativa extract standardized to contain 0.1%-5% w/w thymoquinone, about 0.01%-10% w/w thymohydroquinone, about 20%-95% w/w fatty acids, about 0.001%-3% w/w α-hederin or hederagenin, and Terminalia arjuna extract standardized to contain 3% w/w arjunoglucosides for use a prostaglandin transporter inhibitor. The invention also discloses the use of the aforementioned composition in the therapeutic management of hypertension and cardiovascular complications.

Description

FIELD OF INVENTION[0001]The invention in general relates to composition comprising plant extracts. More specifically the present invention pertains to compositions for inhibiting prostaglandin transporter (PGT) and related therapeutic applications.BACKGROUND OF THE INVENTION[0002]Prostaglandins (PGs) are naturally occurring unsaturated fatty acids which are implicated in mediating a variety of pathophysiological processes and homeostatic functions in different organs. They are derived from arachidonic acid by the action of cyclooxygenase isoenzymes. Principally, there are 4 bioactive PGs ubiquitously produced: prostaglandin E2 (PGE2), prostacyclin (PGI2), prostaglandin D2 (PGD2), and prostaglandin F2α (PGF2α), acting as autocrine and paracrine mediators to maintain homeoastatic functions in the body (Ricciotti et al., Prostaglandins and Inflammation, Arteriosclerosis, Thrombosis, and Vascular Biology. 2011; 31:986-1000). PGs play a main role in regulating many disease conditions in ...

AI Technical Summary

Benefits of technology

[0014]More specifically, the invention discloses a composition comprising effective doses of Allium sativum extract standardized to contain not less than 0.3% w / w S-allylcysteine, Beta vulgaris extract standardized to contain not less than 2% w / w nitrates, Nigella sativa extract standardized to contain 0.1%-5% w / w thymoquinone, about 0.01%-10% w / w thymohydroquinone, about 20%-95% w / w fatty acids, about 0.001%-3% w / w α-hederin or hederagenin, and Terminalia arjuna extract standardized to contain 3% w / w arjunoglucosides for use a PGT inhibitor

[0015]The invention also discloses a method for the therapeutic management of hypertension in mammals using a composition comprising Allium sativum extract standardized to contain not less than 0.3% w / w S-allylcysteine, Beta vulgaris extract standardized to contain not less than 2% w / w nitrates, Nigella sativa extract standardized to contain 0.1%-5% w / w thymoquinone, about 0.01%-10% w / w thymohydroquinone, about 20%-95% w / w fatty acids, about 0.001%-3% w / w α-hederin or hederagenin, and Terminalia arjuna extract standardized to contain 3% w / w arjunoglucosides.

[0016]In another aspect, the invention discloses a method for conferring cardio protection in mammals using a composition comprising Allium sativum extract standardized to contain not less than 0.3% w / w S-allylcysteine, Beta vulgaris extract standardized to contain not less than 2% w / w nitrates, Nigella sativa extract standardized to contain 0.1%-5% w / w thymoquinone, about 0.01%-10% w / w thymohydroquinone, about 20%-95% w / w fatty acids, about 0.001%-3% w / w α-hederin or hederagenin, and Terminalia arjuna extract standardized to contain 3% w / w arjunoglucosides.

Problems solved by technology

However, these synthetic drugs have increased side effects and there exists a need for a safe and natural alternative to mitigate the effects of PGs by inhibiting PGT.

Images